Development of T-cell memory against inhalant allergens: risks for the future.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Development of T-cell memory against inhalant allergens: risks for the future.

Clin Exp Allergy. 1999 Jun;29 Suppl 2:8-13. Unique Identifier : AIDSLINE MED/99352269
Holt PG; Department of Cell Biology, TVW Telethon Institute for Child; Health Research, West Perth, Australia.

Abstract: Recent evidence suggests that the development of chronic allergic respiratory disease is a biphasic process. Phase 1 commonly occurs during early childhood and in many instances appears to be initiated in utero. This involves initial priming of the Th-cell system against ubiquitous environmental allergens, and subsequent reshaping of these responses during infancy into Th1- or Th2-polarized immunological memory. The second phase of the process comprises the repeated expression of Th2-polarized allergen-specific immunity at the level of the airway mucosa, producing cumulative damage to local tissue resulting ultimately in phenotypic changes including development of airways hyperreactivity. It is also clear that this second phase occurs in only a relatively small subset of subjects who develop long-term Th2-polarized allergen-specific immunity, given that the majority of skin prick test positive subjects do not develop chronic airways disease. This suggests that an additional set of control mechanisms, which regulate the intensity/duration of local Th-cell responses within airway mucosal tissues, may play an important role in the ultimate expression of chronic immunoinflammatory disease in the airways in 'at risk' atopic subjects.

Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Air Pollutants, Environmental/*IMMUNOLOGY Allergens/*IMMUNOLOGY Animal Bronchial Hyperreactivity/*IMMUNOLOGY Dendritic Cells/IMMUNOLOGY Human Immunity *Immunologic Memory Risk Factors Th1 Cells/*IMMUNOLOGY Th2 Cells/*IMMUNOLOGY
991030
A99A0926

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .